Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

Open access
Wilcock, G., M??bius, H.J., St??ffler, A. · 2002 · International Clinical Psychopharmacology

Abstract

The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist. Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion. Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C). A total of 579 patients were randomized and 548 patients with at least one post-baseline efficacy assessment qualified for the intent-to-treat analysis. At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. A total of 77% of all memantine-treated patients experienced adverse event, versus 75% of the placebo-treated patients, dizziness being the most frequent adverse event (11% versus 8%, respectively). Memantine was well tolerated and safe.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-200211000-00005

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 8

  1. Forette, 1991, Aging, 3, 373???382
  2. Gottfries, 1982, Arch Gerontol Geriatr, 1, 311???330
  3. Hachinski, 1994, Dementia, 5, 130???132
  4. Hamilton, 1960, J Neurol Neurosurg Psychiatry, 23, 56???62
  5. Mohs, 1988, Psychopharmacol Bull, 24, 627???628
  6. Pantoni, 1999, Alzheimer Dis Assoc Disord, 13, S49???S54
  7. Rom??n, 1993, Neurology, 43, 250???260
  8. Winblad, 1999, Int J Geriatr Psychiatry, 14, 135???146

Cited by

See all 382

Metadata

Authors
Wilcock, G., M??bius, H. J., & St??ffler, A.
Affiliations
Frenchay Hospital (GB)
Venue
International Clinical Psychopharmacology
Published
2002-11
Volume
17
Issue
6
Pages
297-305
ISSN
0268-1315 (ISSN-L)
OpenAlex
W1990057142
Cited by
381
References
25
Citations by year
2026: 10 · 2025: 6 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 47 · 2019: 15 · 2018: 12 · 2017: 11 · 2016: 8 · 2015: 14 · 2014: 15 · 2013: 15 · 2012: 10
FWCI
12.40
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • UWE Research Repository (UWE Bristol) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
memantine, vascular dementia, NMDA receptor antagonists, cognitive function, drug safety, adverse events, dizziness, Mini-Mental State Examination, ADAS-Cog, Clinical Global Impression of Change, treatment efficacy
MeSH terms
Aged, Aged, 80 and over, Antiparkinson Agents, Cognition, Dizziness, Double-Blind Method, Female, Humans, Male, Memantine, Mental Status Schedule, Placebos, Dementia, Vascular, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). https://app.cochat.ai/papers/10.1097/00004850-200211000-00005
The paper
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200211000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.